Pan Xiaofen, Zhu Mengyuan, Huang Guihao, Li Xueying, Liao Jiehao, Huang Shan, Wang Bo
Department of Oncology, The Seventh Affiliated Hospital, Sun Yat-Sen University, No. 628, Zhenyuan Road, Guangming District, Shenzhen, 518107, China.
Support Care Cancer. 2025 Mar 11;33(4):268. doi: 10.1007/s00520-025-09333-9.
To study the safety of resuming antitumor therapy in tumor patients infected with COVID-19.
We collected the clinical information of patients with tumors who were infected with COVID-19 and resume antitumor therapy between December 2022 and June 2023. Information about antitumor therapy, COVID-19-related symptoms, laboratory tests, antitumor therapy-related adverse events (AEs), and re-infection with COVID-19 were recorded. Primary endpoints included the incidence of AEs and re-infection of COVID-19. The secondary endpoints included the incidence and duration of COVID-19 related symptoms.
The most common COVID-19 symptoms were fever (39.5%), cough (37.2%), and fatigue (44.2%). Most patients' symptoms lasted no more than a week Two patients were re-infected with COVID-19. All-grade AEs with an incidence rate > 10% included anemia, increased gamma-glutamyl transferase (GGT), anorexia, neutropenia, hypocalcemia, leukopenia, thrombocytopenia, increased alanine aminotransferase, increased aspartate aminotransferase, hypokalemia, hyponatremia, and nausea. Grade 3-4 AEs with an incidence rate higher than 5% included anemia, neutropenia, leukopenia, thrombocytopenia, anorexia, and vomiting. The incidence of AEs before and after COVID-19 infection did not show a significant difference.
Resuming antitumor therapy early after SARS-CoV-2 test turned negative did not increase antitumor therapy-related AEs or the incidence of re-infection in COVID-19 infection patients.
研究感染新型冠状病毒肺炎（COVID-19）的肿瘤患者恢复抗肿瘤治疗的安全性。
我们收集了2022年12月至2023年6月期间感染COVID-19并恢复抗肿瘤治疗的肿瘤患者的临床信息。记录了抗肿瘤治疗、COVID-19相关症状、实验室检查、抗肿瘤治疗相关不良事件（AE）以及再次感染COVID-19的信息。主要终点包括AE的发生率和再次感染COVID-19的情况。次要终点包括COVID-19相关症状的发生率和持续时间。
最常见的COVID-19症状为发热（39.5%）、咳嗽（37.2%）和乏力（44.2%）。大多数患者的症状持续不超过一周。两名患者再次感染了COVID-19。发生率>10%的所有级别的AE包括贫血、γ-谷氨酰转移酶（GGT）升高、厌食、中性粒细胞减少、低钙血症、白细胞减少、血小板减少、丙氨酸氨基转移酶升高、天冬氨酸氨基转移酶升高、低钾血症、低钠血症和恶心。发生率高于5%的3-4级AE包括贫血、中性粒细胞减少、白细胞减少、血小板减少、厌食和呕吐。COVID-19感染前后AE的发生率无显著差异。
SARS-CoV-2检测转为阴性后尽早恢复抗肿瘤治疗，不会增加COVID-19感染患者抗肿瘤治疗相关AE或再次感染的发生率。
